![Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward! | The Egyptian Heart Journal | Full Text Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward! | The Egyptian Heart Journal | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs43044-022-00259-9/MediaObjects/43044_2022_259_Fig1_HTML.png)
Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward! | The Egyptian Heart Journal | Full Text
![Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward! | The Egyptian Heart Journal | Full Text Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward! | The Egyptian Heart Journal | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs43044-022-00259-9/MediaObjects/43044_2022_259_Fig2_HTML.png)
Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward! | The Egyptian Heart Journal | Full Text
![Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward! | The Egyptian Heart Journal | Full Text Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward! | The Egyptian Heart Journal | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs43044-022-00259-9/MediaObjects/43044_2022_259_Fig3_HTML.png)
Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward! | The Egyptian Heart Journal | Full Text
![Switching from warfarin to NOAC. NOAC, non-vitamin K antagonist oral... | Download Scientific Diagram Switching from warfarin to NOAC. NOAC, non-vitamin K antagonist oral... | Download Scientific Diagram](https://www.researchgate.net/publication/330931168/figure/fig2/AS:723659262025728@1549545221292/Switching-from-warfarin-to-NOAC-NOAC-non-vitamin-K-antagonist-oral-anticoagulant-INR.png)
Switching from warfarin to NOAC. NOAC, non-vitamin K antagonist oral... | Download Scientific Diagram
CorConsult Rx - #Repost @ambcarerx ・・・ Oral Anticoagulants have many chronic indications, most commonly VTE treatment/prophylaxis, atrial fibrillation, and valvular heart disease. VTE & AF can both be treated with either warfarin
![JCM | Free Full-Text | Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation JCM | Free Full-Text | Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation](https://www.mdpi.com/jcm/jcm-10-02866/article_deploy/html/images/jcm-10-02866-g004.png)
JCM | Free Full-Text | Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation
![Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study - ScienceDirect Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0272638622006217-fx1.jpg)
Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study - ScienceDirect
![Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis - ScienceDirect Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1936879819318552-gr4.jpg)
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis - ScienceDirect
![JCM | Free Full-Text | Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation JCM | Free Full-Text | Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation](https://www.mdpi.com/jcm/jcm-13-01073/article_deploy/html/images/jcm-13-01073-g001.png)